Navigation Links
Ariosa Diagnostics Announces Nationwide Launch of the Harmony™ Prenatal Test Through LabCorp
Date:5/7/2012

SAN JOSE, Calif., May 7, 2012 /PRNewswire/ -- Ariosa Diagnostics, a molecular diagnostics company, today announced that the Harmony Prenatal Test will be available in the United States and Canada through Laboratory Corporation of America® Holdings (LabCorp®) and Integrated Genetics, a member of LabCorp's Specialty Testing Group. Harmony represents an innovative non-invasive test for detection of common fetal trisomies utilizing a directed approach to analyze cell-free DNA (cfDNA) in maternal blood. The Harmony Prenatal Test is currently available in selected locations and will be broadly available next month.

(Logo: http://photos.prnewswire.com/prnh/20120326/NY75864LOGO)

"Ariosa Diagnostics is very excited to announce the official launch of the Harmony Prenatal Test and the agreement with LabCorp, which helps us deliver on the promise of bringing an affordable and accessible prenatal testing option to pregnant women and their physicians," said Ken Song, MD, chief executive officer at Ariosa Diagnostics. "With enhanced test performance and simplicity, the Harmony Prenatal Test can be reliably incorporated into the management of pregnancies."

The Harmony Prenatal Test, which detects common fetal trisomies such as Trisomy 21 (associated with Down syndrome), will be offered through LabCorp and will be available at its 1,000+ patient service centers. The test is performed using a simple maternal blood draw taken at a doctor's office or patient service center, and provides the safety of screening tests with accuracy approaching that of invasive testing for common fetal trisomies. The test is available to pregnant women of at least 10 weeks gestational age with a single fetus conceived without the use of an egg donor.

"We are pleased to be able to offer this novel, non-invasive prenatal test," indicated Mark Brecher, MD, LabCorp's chief medical officer. "Ariosa Diagnostics' Harmony Prenatal Test adds another option to LabCorp's comprehensive prenatal testing menu."

"The Harmony Prenatal Test is an affordable, high-quality test that provides a new choice for women," said Dr. Song. "Together with LabCorp, we are committed to ensuring that the latest advances in prenatal testing are accessible to all healthcare providers and women."

About Ariosa Diagnostics (formerly Aria Diagnostics)

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to providing safe, highly accurate and affordable prenatal tests for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. Ariosa's simple blood test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com.

*Integrated Genetics is a business unit of Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of Laboratory Corporation of America Holdings.


'/>"/>
SOURCE Ariosa Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
2. VentriPoint Diagnostics Files Management Discussion and Analysis, Unaudited Financial Results for 2Q 2008
3. Exosome Diagnostics Announces Additions to Management Team
4. Pathwork Diagnostics Closes $20M Financing
5. Boveran Diagnostics, Inc. Announces Planned Acquisition of New York-Based Pathology Lab: Sophora Diagnostic Lab, Inc.
6. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
7. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
8. Enigma Diagnostics Announces an Award of GBP 1.8 Million From UK Government
9. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
10. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
11. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology ... cancer vaccines, today announced participation at the following conferences: ... Blair and Maidstone Life Sciences conference "Cancer Immunotherapy Conference" ... New York, NY . Agenus will participate ... 9:40 am: Robert B. Stein , M.D., Ph.D., ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseq™ Inherited Cancer DNA ... from industry experts to validate the ability ...
(Date:3/23/2017)... NEW YORK , March 23, 2017 ... ... causes of death, putting significant strain on health care systems, ... of cancer diagnoses rises, so too does the development of ... with minimum side effects. Among the many types of cancer ...
(Date:3/22/2017)... N.Y. , March 22, 2017 Regeneron Pharmaceuticals, ... the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to ... the U.K. Biobank resource. The initiative will enable researchers to ... new medicines for a wide range of serious and life ... ...
Breaking Biology Technology:
(Date:2/27/2017)... --  Strategic Cyber Ventures , the industry,s first cybersecurity ... million investment in  Polarity , the first commercial human ... based and is led by cybersecurity veterans Tom ... Gula , also a longtime cybersecurity veteran and founder ... A round of funding. This new funding will be ...
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
Breaking Biology News(10 mins):